Article Information
History
- September 4, 2024.
Article Versions
- Version 1 (August 16, 2024 - 11:31).
- Version 2 (August 20, 2024 - 01:36).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Skylar Petrichko1,*,
- Jason Kindrachuk2,*,
- Dalau Nkamba3,
- Megan Halbrook1,
- Sydney Merritt1,
- Handdy Kalengi3,
- Leonard Kamba3,
- Michael Beya3,
- Nicole A. Hoff1,
- Christophe Luhata4,
- Didine K. Kaba3,# and
- Anne W. Rimoin1,#,†
- 1Department of Epidemiology, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles, CA, USA
- 2Department of Medical Microbiology & Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada
- 3Kinshasa School of Public Health, University of Kinshasa, Democratic Republic of the Congo
- 4Expanded Programme for Immunization, Ministry of Health, Democratic Republic of the Congo
- ↵†Corresponding Author: Anne W. Rimoin, PhD, MPH, Professor, Department of Epidemiology, Gordon-Levin Endowed Chair in Infectious Diseases and Public Health, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles 650 Charles E. Young Dr, CHS 41-275, Los Angeles, CA, 90095, +1 (310) 825-2096, arimoin{at}ucla.edu
↵* Denotes co-first authors. These authors contributed equally to this article.
Posted September 04, 2024.
Acceptance of an Mpox Vaccine in the Democratic Republic of the Congo: Results from a Nationwide Phone Survey
